[
  {
    "ts": null,
    "headline": "Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure",
    "summary": "Arvinas (ARVN) shares fell 5.7% in recent Friday trading after the company outlined plans for a data",
    "url": "https://finnhub.io/api/news?id=9d1811550b9f7d328907d3ec012a9dc46cf853a57e5b97ed907ef7e9355458e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736537823,
      "headline": "Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure",
      "id": 132371618,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Arvinas (ARVN) shares fell 5.7% in recent Friday trading after the company outlined plans for a data",
      "url": "https://finnhub.io/api/news?id=9d1811550b9f7d328907d3ec012a9dc46cf853a57e5b97ed907ef7e9355458e3"
    }
  },
  {
    "ts": null,
    "headline": "Court Reopens Challenge to Pfizer Fellowship Program Amid Diversity Debate",
    "summary": "U.S. court reopens Pfizer fellowship lawsuit amid growing scrutiny of diversity programs",
    "url": "https://finnhub.io/api/news?id=8aed5b704fb05c86a42fe17a95a56d65cbeb60c4bfc55ed7b48aa3b7ec8f457e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736534530,
      "headline": "Court Reopens Challenge to Pfizer Fellowship Program Amid Diversity Debate",
      "id": 132371621,
      "image": "https://s.yimg.com/ny/api/res/1.2/LtDRrn.pCFlCkdaClzYgEA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD01Mjk-/https://media.zenfs.com/en/us.finance.gurufocus/896904febd776c0eb87d0b1509bf1053",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "U.S. court reopens Pfizer fellowship lawsuit amid growing scrutiny of diversity programs",
      "url": "https://finnhub.io/api/news?id=8aed5b704fb05c86a42fe17a95a56d65cbeb60c4bfc55ed7b48aa3b7ec8f457e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer must face lawsuit over diversity fellowship program, US court rules",
    "summary": "(Reuters) -A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that challenged a Pfizer fellowship program designed to boost the pipeline of Black, Latino and Native American people in leadership positions at the drugmaker.  At the urging of the group Do No Harm, a 2-1 panel of the New York-based 2nd U.S. Circuit Court of Appeals revisted a decision it issued last year holding the organization lacked legal standing to challenge the drugmaker's program in court.",
    "url": "https://finnhub.io/api/news?id=760b3a7502789db7abcd617bd6f5f8fcb76ffe811b64bb4afebbe475f9f73dc1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736532935,
      "headline": "Pfizer must face lawsuit over diversity fellowship program, US court rules",
      "id": 132371622,
      "image": "https://media.zenfs.com/en/reuters.com/3d3ae3f7b4ca68ca8ffb36916f0e00d4",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Reuters) -A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that challenged a Pfizer fellowship program designed to boost the pipeline of Black, Latino and Native American people in leadership positions at the drugmaker.  At the urging of the group Do No Harm, a 2-1 panel of the New York-based 2nd U.S. Circuit Court of Appeals revisted a decision it issued last year holding the organization lacked legal standing to challenge the drugmaker's program in court.",
      "url": "https://finnhub.io/api/news?id=760b3a7502789db7abcd617bd6f5f8fcb76ffe811b64bb4afebbe475f9f73dc1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial",
    "summary": "On Friday, Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance for BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint of event-free survival by investigator assessment, showing a clinically meaningful and statistically significant improvement with",
    "url": "https://finnhub.io/api/news?id=a3f9bc5d8863f98dd127d6b6fda540769ef3e5b3a2e469b0ecdf1b58b1208793",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736529581,
      "headline": "Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial",
      "id": 132367227,
      "image": "https://media.zenfs.com/en/Benzinga/3bee134322783ce381307d57013958e6",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On Friday, Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance for BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint of event-free survival by investigator assessment, showing a clinically meaningful and statistically significant improvement with",
      "url": "https://finnhub.io/api/news?id=a3f9bc5d8863f98dd127d6b6fda540769ef3e5b3a2e469b0ecdf1b58b1208793"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Friday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=482ec0a899af340ec406a1fa1a2ac6ab6fc5b6046c2d4ed4c9728314ef487c6b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736527020,
      "headline": "Pfizer Inc. stock underperforms Friday when compared to competitors",
      "id": 132409897,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=482ec0a899af340ec406a1fa1a2ac6ab6fc5b6046c2d4ed4c9728314ef487c6b"
    }
  },
  {
    "ts": null,
    "headline": "AI, vaccine distrust, & the future of healthcare: Novartis CEO",
    "summary": "Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline in areas like heart disease and cancer. Still, Narasimhan is feeling pressure to bring the investments to the bottom line to jumpstart a stock price that has lagged in the past year. For full episodes of Opening Bid, listen on your favorite podcast platform or watch on our website.",
    "url": "https://finnhub.io/api/news?id=be29e0e1d1de1f0cf67bbfce15ae9d05e3410ad5a5cd4340317e7ad82a5f045e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736515851,
      "headline": "AI, vaccine distrust, & the future of healthcare: Novartis CEO",
      "id": 132363849,
      "image": "https://s.yimg.com/ny/api/res/1.2/lYz92SON.CgZn.4L3FSanQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzQ-/https://s.yimg.com/os/creatr-uploaded-images/2025-01/c2a28a10-ced6-11ef-8ffe-41aa770da203",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline in areas like heart disease and cancer. Still, Narasimhan is feeling pressure to bring the investments to the bottom line to jumpstart a stock price that has lagged in the past year. For full episodes of Opening Bid, listen on your favorite podcast platform or watch on our website.",
      "url": "https://finnhub.io/api/news?id=be29e0e1d1de1f0cf67bbfce15ae9d05e3410ad5a5cd4340317e7ad82a5f045e"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal",
    "summary": "FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.",
    "url": "https://finnhub.io/api/news?id=dd322791b050c377ae7f5c8565f7cb0f163387efa7f22edd9437f95617a60852",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736514600,
      "headline": "Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal",
      "id": 132365169,
      "image": "https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.",
      "url": "https://finnhub.io/api/news?id=dd322791b050c377ae7f5c8565f7cb0f163387efa7f22edd9437f95617a60852"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer",
    "summary": "NEW YORK, January 10, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a c",
    "url": "https://finnhub.io/api/news?id=34f60c6021c1d0c23ad0105590e03850421f23b0c84be7ab3a49ccc9c364226c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736509500,
      "headline": "Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer",
      "id": 132365171,
      "image": "https://media.zenfs.com/en/business-wire.com/a68db685618dbab873a4d8751470d8eb",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, January 10, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a c",
      "url": "https://finnhub.io/api/news?id=34f60c6021c1d0c23ad0105590e03850421f23b0c84be7ab3a49ccc9c364226c"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets",
    "summary": "Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire.",
    "url": "https://finnhub.io/api/news?id=c07693953a57098badbae424aa4662c47581d1f9f7e396d22552086923970693",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736509380,
      "headline": "Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets",
      "id": 132365554,
      "image": "https://imgproxy.divecdn.com/EK5xKj0ydykvmwFmBqsauREtdhrHAUsAiyI6JgDkO1s/g:nowe:0:0/c:1207:682/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDgzOTIxNzkzLmpwZw==.webp",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire.",
      "url": "https://finnhub.io/api/news?id=c07693953a57098badbae424aa4662c47581d1f9f7e396d22552086923970693"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: positive results in bladder cancer",
    "summary": "On Friday, Pfizer announced positive results from a Phase III study of its proposed monoclonal antibody, sasanlimab, in the treatment of bladder cancer.In a press release, the US pharmaceutical group...",
    "url": "https://finnhub.io/api/news?id=34a609e7e98ea97e20f4f0a616963ae9a91c8f491a3f08f1a9332aa6f18635f4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736505311,
      "headline": "Pfizer: positive results in bladder cancer",
      "id": 132364115,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "On Friday, Pfizer announced positive results from a Phase III study of its proposed monoclonal antibody, sasanlimab, in the treatment of bladder cancer.In a press release, the US pharmaceutical group...",
      "url": "https://finnhub.io/api/news?id=34a609e7e98ea97e20f4f0a616963ae9a91c8f491a3f08f1a9332aa6f18635f4"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Sasanlimab Hits Late-Stage Study Primary Endpoint for Bladder Cancer",
    "summary": "By Colin Kellaher Pfizer said a late-stage study of its sasanlimab drug candidate met its key goal in certain patients with bladder cancer. Pfizer on Friday said the pivotal Phase 3 study...",
    "url": "https://finnhub.io/api/news?id=21d46cfd85d65105030fd67b76a06dbdc141a3e43ed66e3225558e1b8b7733a6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736498593,
      "headline": "Pfizer's Sasanlimab Hits Late-Stage Study Primary Endpoint for Bladder Cancer",
      "id": 132362924,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Pfizer said a late-stage study of its sasanlimab drug candidate met its key goal in certain patients with bladder cancer. Pfizer on Friday said the pivotal Phase 3 study...",
      "url": "https://finnhub.io/api/news?id=21d46cfd85d65105030fd67b76a06dbdc141a3e43ed66e3225558e1b8b7733a6"
    }
  },
  {
    "ts": null,
    "headline": "Silent Dangers: The Link Between Depo-Provera, Brain Tumors, And Health Inequities",
    "summary": "For decades, Depo-Provera has been presented as a game-changing contraceptive—a quick injection every three months that promised simplicity and effectiveness. For millions of women worldwide, it...",
    "url": "https://finnhub.io/api/news?id=18f6ab827cdd9c5a1bf93cef5f47501357b7cc4da2ae88fe3b514c40fc1bef24",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736493007,
      "headline": "Silent Dangers: The Link Between Depo-Provera, Brain Tumors, And Health Inequities",
      "id": 132361870,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "For decades, Depo-Provera has been presented as a game-changing contraceptive—a quick injection every three months that promised simplicity and effectiveness. For millions of women worldwide, it...",
      "url": "https://finnhub.io/api/news?id=18f6ab827cdd9c5a1bf93cef5f47501357b7cc4da2ae88fe3b514c40fc1bef24"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's bladder cancer therapy meets main goal in late-stage study",
    "summary": "Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications, including cancer recurrence, the drugmaker said on...",
    "url": "https://finnhub.io/api/news?id=a4840637436a0bf3d2a35f96b79d67b29588ab317815607abe960bd05a2be8b0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736491852,
      "headline": "Pfizer's bladder cancer therapy meets main goal in late-stage study",
      "id": 132361710,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications, including cancer recurrence, the drugmaker said on...",
      "url": "https://finnhub.io/api/news?id=a4840637436a0bf3d2a35f96b79d67b29588ab317815607abe960bd05a2be8b0"
    }
  },
  {
    "ts": null,
    "headline": "The CEOs Who Are Tearing Up the Policies Trump Hates",
    "summary": "Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate initiatives; ‘EVERYBODY WANTS TO BE MY FRIEND!!!’",
    "url": "https://finnhub.io/api/news?id=72b2ff7dc69e17136a7941de02cea0ec855eac418f7e568725527e4ac7749436",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736474400,
      "headline": "The CEOs Who Are Tearing Up the Policies Trump Hates",
      "id": 132355621,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate initiatives; ‘EVERYBODY WANTS TO BE MY FRIEND!!!’",
      "url": "https://finnhub.io/api/news?id=72b2ff7dc69e17136a7941de02cea0ec855eac418f7e568725527e4ac7749436"
    }
  }
]